The Nebraska Department of Health and Human Services Immunization Program aims to protect people against known and emerging infectious diseases here in Nebraska. COVID-19 has greatly impacted the lives of all Nebraskans and this program intends to provide the COVID-19 vaccine when it is made available for allocation. The CDC believes that the COVID-19 vaccine will be limited and therefore should be allocated in a phased approach.
If a Nebraska provider is interesting in offering the COVID-19 vaccine once vaccine availability has increased, please complete this survey to determine if you meet the requirements.
State of Nebraska COVID-19 Vaccination PlanUPDATED: 2/22/2021
Vaccine Information for the General Public
Thank you for your willingness to administer the COVID 19 vaccine to help protect the public.
The Nebraska Immunization Program is currently allocating vaccine to enrolled COVID-19 Vaccine Phase 1 providers. When the program is ready to begin Phase 2, we will contact potential providers for further information.
All facilities interested in becoming a COVID-19 Vaccine Provider MUST complete this survey.
There are no federal or state requirements that a consent has to be obtained. You do however have to provide the VIS or in this case the EUA fact sheet and document the date it was given. If your facility has an internal process that is utilized for other immunizations, we recommend using that process.
The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):
The vaccination provider enrolled in the federal COVID-19 Vaccination Program should complete and submit a VAERS form to FDA using one of the following methods:
IMPORTANT: When reporting adverse events or vaccine administration errors to VAERS, please complete the entire form with detailed information. It is important that the information reported to FDA be as detailed and complete as possible. Information to include:
Outcome of the event and any additional follow-up information if it is available at the time of the VAERS report. Subsequent reporting of follow-up information should be completed if additional details become available.
Refer to the reference tools for material on how to properly manage the vaccines.
If you are unsure on the integrity of vaccine in your possession, please call Pfizer Customer Service at 800-666-7248 (option 8) or email CVGovernment@pfizer.com .
This information will be updated as needed if additional product specific details are made available.